การจัดการทาลัสซีเมีย
เชิงอรรถและอ้างอิง

1 2   "Pediatric Thalassemia Treatment & Management". Medical Care. Open Publishing. 30 April 2010. สืบค้นเมื่อ 27 September 2011.
↑   Burdick, Claude Owen. "Separating Thalassemia Trait and Iron Deficiency by Simple Inspection". American Society for Clinical Pathology. สืบค้นเมื่อ 27 September 2011.
↑  Harrison's Principles of Internal Medicine 17th Edition. McGraw-Hill medical. September 2008. p. 776. ISBN 0-07-164114-9.
↑  Aisen, P; Leibman, A; Zweier, J; Leibman; Zweier (March 1978). "Stoichiometric and site characteristics of the binding of iron to human transferrin". J. Biol. Chem. 253 (6): 1930–7. PMID 204636.{{cite journal}}:  CS1 maint: multiple names: authors list (ลิงก์)
1 2 3 4 5  Brittenham, Gary M; Olivieri, Nancy F (1997). "Iron-chelating therapy and the treatment of thalassemia". Journal of the American Society of Hematology. 89 (3): 739–761. PMID 9028304. สืบค้นเมื่อ 28 February 2013.
↑  Brittenham, Gary M.; Griffith, Patricia M.; Nienhuis, Arthur W.; McLaren, Christine E.; Young, Neal S.; Tucker, Eben E.; Allen, Christopher J.; Farrell, David E.; Harris, John W. (1994). "Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major". New England Journal of Medicine. 331 (9): 567–73. doi:10.1056/NEJM199409013310902. PMID 8047080.
↑  Cozar, O.; Leopold, N.; Jelic, C.; Chiş, V.; David, L.; Mocanu, A.; Tomoaia-Cotişel, M. (2006). "IR, Raman and surface-enhanced Raman study of desferrioxamine B and its Fe (III) complex, ferrioxamine B". Journal of Molecular Structure. 788: 1. Bibcode:2006JMoSt.788....1C. doi:10.1016/j.molstruc.2005.04.035.
↑  Cohen, Alan; Martin, Marie; Schwartz, Elias (1981). "Response to long-term deferoxamine therapy in thalassemia". The Journal of Pediatrics. 99 (5): 689–94. doi:10.1016/S0022-3476(81)80385-X. PMID 7299539.
↑  Pennell, D. J.; Berdoukas, V; Karagiorga, M; Ladis, V; Piga, A; Aessopos, A; Gotsis, ED; Tanner, MA;  และคณะ (2006). "Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis". Blood. 107 (9): 3738–44. doi:10.1182/blood-2005-07-2948. PMID 16352815.
↑  Jin, Haiyan; Terai, Shuji; Sakaida, Isao (2007). "The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis". Journal of Gastroenterology. 42 (6): 475–84. doi:10.1007/s00535-007-2020-5. PMID 17671763.
↑  Kaye, Todd B.; Guay, André T.; Simonson, Donald C. (1993). "Non-insulin-dependent diabetes mellitus and elevated serum ferritin level". Journal of Diabetes and its Complications. 7 (4): 245. doi:10.1016/S0002-9610(05)80252-1.
↑  Olivieri, Nancy F.; Koren, Gideon; Harris, Jonathan; Khattak, Sohail; Freedman, Melvin H.; Templeton, Douglas M.; Bailey, John D.; Reilly, B. J. (1992). "Growth Failure and Bony Changes Induced by Deferoxamine". Journal of Pediatric Hematology/Oncology. 14: 48. doi:10.1097/00043426-199221000-00007.
↑  Ambruso, DR; Mahony, BS; Githens, JH; Rhoades, ED (1982). "Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome". The American journal of pediatric hematology/oncology. 4 (2): 115–23. PMID 7114394.
↑  Kattamis, Antonis (2005). "Combined therapy with deferoxamine and deferiprone". Annals of the New York Academy of Sciences. 1054: 175–82. Bibcode:2005NYASA1054..175K. doi:10.1196/annals.1345.020. PMID 16339663.
1 2 3 4 5 6 7 8 9  Wiwanitkit, Viroj (2006). "Quantum chemical analysis of the deferiprone-iron binding reaction". International Journal of Nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
1 2  
Olivieri, Nancy F.; Brittenham, Gary M. (1997). "Iron-Chelating Therapy and the Treatment of Thalassemia". Blood. 89 (3): 739–61. PMID 9028304.
1 2  Galanello, R.; Campus, S. (2009). "Deferiprone Chelation Therapy for Thalassemia Major". Acta Haematologica. 122 (2–3): 155–64. doi:10.1159/000243800. PMID 19907153.
↑  Wiwanitkit, Viroj (2006). "Quantum Chemical Analysis of the Deferiprone-Iron Binding Reaction". International journal of nanomedicine. 1 (1): 111–3. doi:10.2147/nano.2006.1.1.111. PMC 2426763. PMID 17722270.
↑  Heli, Hossein; Mirtorabi, Siamak; Karimian, Khashayar (2011). "Advances in iron chelation: An update". Expert Opinion on Therapeutic Patents. 21 (6): 819–56. doi:10.1517/13543776.2011.569493. PMID 21449664.
↑  Cappellini, M. D.; Cohen, A; Piga, A; Bejaoui, M; Perrotta, S; Agaoglu, L; Aydinok, Y; Kattamis, A;  และคณะ (2006). "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia". Blood. 107 (9): 3455–62. doi:10.1182/blood-2005-08-3430. PMID 16352812.
↑  R Galanello; Piga, A; Forni, GL; Bertrand, Y; Foschini, ML; Bordone, E; Leoni, G; Lavagetto, A;  และคณะ (2006-01-01). "Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major". Haematologica. 91 (10): 1343–51. PMID 17018383.
↑  Nisbet-Brown, Eric; Olivieri, Nancy F; Giardina, Patricia J; Grady, Robert W; Neufeld, Ellis J; Séchaud, Romain; Krebs-Brown, Axel J; Anderson, Judith R;  และคณะ (2003). "Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial". The Lancet. 361 (9369): 1597. doi:10.1016/S0140-6736(03)13309-0.
1 2 3  Cappellini, M. D.; Bejaoui, M.; Agaoglu, L.; Canatan, D.; Capra, M.; Cohen, A.; Drelichman, G.; Economou, M.;  และคณะ (2011). "Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up". Blood. 118 (4): 884–93. doi:10.1182/blood-2010-11-316646. PMID 21628399.
↑  "How Are Thalassemias Treated?". National Heat, Lung and Blood institute. สืบค้นเมื่อ 2 March 2013.
1 2 3 4  Tesoriere, L.; Allegra, M.; Butera, D.; Gentile, C.; Livrea, M. A. (2006). "Cytoprotective effects of the antioxidant phytochemical indicaxanthin in β-thalassemia red blood cells". Free Radical Research. 40 (7): 753–61. doi:10.1080/10715760600554228. PMID 16984002.
↑  Leung, TN; Lau, TK; Chung, TKH (April 2005). "Thalassaemia screening in pregnancy". Current Opinion in Obstetrics and Gynecology. 17 (2): 129–34. doi:10.1097/01.gco.0000162180.22984.a3. PMID 15758603.{{cite journal}}:  CS1 maint: multiple names: authors list (ลิงก์)
↑  Samavat, A; Modell, B; Modell (November 2004). "Iranian national thalassaemia screening programme". BMJ (Clinical Research Ed.). 329 (7475): 1134–7. doi:10.1136/bmj.329.7475.1134. PMC 527686. PMID 15539666.{{cite journal}}:  CS1 maint: multiple names: authors list (ลิงก์)
↑  "Spanish Baby Engineered To Cure Brother". October 2008. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 4 December 2008.
↑  "His sister's keeper: Brother's blood is boon of life". Times of India. 17 September 2009.
↑  Sabloff, M; Chandy, M; Wang, Z; Logan, BR; Ghavamzadeh, A; Li, CK; Irfan, SM; Bredeson, CN;  และคณะ (2011). "HLA-matched sibling bone marrow transplantation for β-thalassemia major". Blood. 117 (5): 1745–50. doi:10.1182/blood-2010-09-306829. PMC 3056598. PMID 21119108.
↑  Sodani, P; Isgrò, A; Gaziev, J; Paciaroni, K; Marziali, M; Simone, MD; Roveda, A; De Angelis, G;  และคณะ (2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric reports. 3 Suppl 2 (Suppl 2): e13. doi:10.4081/pr.2011.s2.e13. PMC 3206538. PMID 22053275.
Deferiprone
Deferasirox
Deferasirox-Iron (III) complex
indicaxanthin ซึ่งเป็นสีเหลืองของผลต้นกระบองเพชร